Truist Financial analyst Joon Lee maintained a Hold rating on AnaptysBio (ANAB – Research Report) on November 6 and set a price target of $20.00. The company’s shares closed yesterday at $15.50.
Lee covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Marinus, and Viking Therapeutics. According to TipRanks, Lee has an average return of 9.5% and a 38.33% success rate on recommended stocks.
In addition to Truist Financial, AnaptysBio also received a Hold from Wedbush’s David Nierengarten in a report issued on November 3. However, on the same day, Guggenheim maintained a Buy rating on AnaptysBio (NASDAQ: ANAB).
See today’s best-performing stocks on TipRanks >>
Based on AnaptysBio’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.46 million and a GAAP net loss of $39.85 million. In comparison, last year the company earned a revenue of $1.22 million and had a GAAP net loss of $32.55 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio (ANAB) Company Description:
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Read More on ANAB:
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- AnaptysBio price target raised to $20 from $18 at Wedbush
- AnaptysBio reports Q3 collaboration revenue $3.3M vs. $1.3M last year
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
